SynthesisFrontiers in pharmacology2025
P2X7 receptor as a key player in pathological pain: insights into Neuropathic, inflammatory, and cancer pain.
Synthesis in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Acupuncture alleviates postoperative hemorrhoid pain by modulating the P2X7/ERK pathway.Purinergic signalling · 2026Article
- Neuroimmune regulation of visceral pain: roles of microglia, purinergic signaling, and neuroinflammation.Frontiers in immunology · 2026Review
- Genetic Variations in the P2X7 Receptor: Opportunities and Challenges for Drug Development.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purinergic P2X7 receptor (P2X7R) is a widely distributed, non-selective ATP-gated ion channel that plays a crucial role in the regulation of neuropathic pain, inflammatory pain, and cancer pain. Understanding the function and mechanisms of P2X7R in these various pain conditions, as well as utilizing P2X7R-targeted treatments, may offer a promising strategy for alleviating or resolving pathological pain. As a result, P2X7R and its antagonists have been the subject of extensive research, leading to the development of several P2X7R antagonists that have shown promising antinociceptive effects in numerous preclinical studies. However, further investigation and development are still necessary to fully realize their therapeutic potential. This review will provide an overview of the structure and function of P2X7R, its role in different pathological pain conditions, and the latest advances in the development of P2X7R antagonists, with the goal of offering new insights into the treatment of pathological pain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.